Occupation or Discipline – Page 4

Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise

3 months ago talkbio0Tagged Arenaria, Biological Factors, Biological Science Disciplines, biopharma financing, Conditional, HilleVax, Investments, LAVA, M&A, mezigitamab, OrbiMed, royalty acquisition, XOMA Royalty

royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment

Merck to Lay Off 6,000 Employees, Reduce Workforce by 8% in $3B Cost-Cutting Move

3 months ago talkbio0Tagged cost-cutting, Gardasil, Keytruda, layoffs, Merck, restructuring

Merck; layoffs; cost-cutting; restructuring; pharmaceuticals; job cuts; Keytruda; Gardasil; workforce reduction

Merck & Co. Targets $3B in Cost Savings Through Restructuring, Including Job Cuts

3 months ago talkbio0Tagged cost-cutting, Financial savings, Investments, Manufacturing, Merck & Co., R&D, restructuring, restructuring charges, Target

Merck & Co.; cost-cutting; $3 billion savings; restructuring; job cuts; 2027 target; restructuring charges; R&D; manufacturing investments

Merck Announces $3 Billion Cost-Cutting and Restructuring Plan

3 months ago talkbio0Tagged Drug Industry, estate, Financial cost, Keytruda, Merck, Q2 2025, restructuring, Transection (procedure)

Merck; cost cutting; restructuring; job cuts; real estate reduction; Keytruda; pharmaceutical industry; Q2 2025 financials

AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia

3 months ago talkbio0Tagged AstraZeneca, Chronic disease, Investments, Manufacturing, R&D, Surgical construction, tariffs, United States, Virginia plant

AstraZeneca; investment; United States; Virginia plant; manufacturing; R&D; tariffs; chronic diseases; job creation; pharmaceuticals

Over One-Third of Biotechs Face Cash Crunch, EY 2025 Report Finds

4 months ago talkbio0Tagged Biological Science Disciplines, Biopharma, capital constraints, cash runway, EY, macroeconomic

biotech; EY report; cash runway; life sciences; capital constraints; biopharma; 2025; macroeconomic uncertainty

Beyond Theory: Real-World AI Wins in Life Science R&D – Faster & Smarter

4 months ago talkbio0Tagged Artificial Intelligence, Biological Science Disciplines, Clinical Trials, Drug Discovery, Efficiency, Financial cost, Infrequent, R&D, trends qualifier

AI in life sciences; R&D efficiency; drug discovery; clinical trials; pharma innovation; 2025 AI trends; cost reduction; rare diseases

IPG Health Leads at Cannes Lions 2025 as Real Chemistry and Ogilvy Health Earn Major Awards

4 months ago talkbio0Tagged Agencies, Cannes, Geographic Locations, Grand Prix, Health, Health & Wellness, Health Care Market, IPG, Ogilvy Health, Science of Chemistry, Vaseline, Verification

Cannes Lions 2025; IPG Health; Real Chemistry; Ogilvy Health; healthcare marketing; agency awards; Health & Wellness Lions; Grand Prix; AREA 23; Vaseline Verified